Meeting
2015 Genitourinary Cancers Symposium
Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).
Authors
Matthew Raymond Smith
Massachusetts General Hospital Cancer Center, Boston, MA
Matthew Raymond Smith , Janet Elizabeth Brown , Karim Fizazi , Laurence Klotz , Gavin M. Marx , Huei Wang , Douglas Warner , Allan Lipton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00321620
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 267)
DOI
10.1200/jco.2015.33.7_suppl.267
Abstract #
267
Poster Bd #
D10
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2014 Genitourinary Cancers Symposium
Denosumab for the prevention of symptomatic skeletal events in patients with castration-resistant advanced prostate cancer: A comparison with skeletal-related events.
First Author: Matthew R. Smith
Poster
2012 Genitourinary Cancers Symposium
Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM).
First Author: Michael E. Rader
Poster
2011 ASCO Annual Meeting
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
First Author: N. D. Shore